Previous 10 | Next 10 |
Before we ring in 2020, December will be ripe for swings in biotech stock prices. 2019 started strong, waned, and then regained momentum amid a slew of successful clinical trial results, several acquisition announcements, and positive drug approval decisions that came often months ahead of the U...
Are there other aspects of the business, somewhat peculiar to the industry involved, which will give the investor important clues as to how outstanding the company may be in relation to its competition? - Philip Fisher One of the most exciting times for bioscience investors is during a p...
The European Medicines Agency (EMA) has accepted for review Amarin's (NASDAQ: AMRN ) marketing application seeking approval for icosapent ethyl (brand name Vascepa in U.S.) as a treatment to reduce the risk of cardiovascular events in high-risk patients who have their cholesterol le...
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that the European Medicines Agency (EMA) has validated the marketing authorization application (M...
Does the company have depth to its management? - Philip Fisher Make no doubt, Amarin Corporation ( AMRN ) is one of the most powerful growth equities of our time. As strong market forces are acting on the company, you should revisit this investment thesis. As you research Amarin, you s...
Following the announcement of positive mid-phase testing for its schizophrenia treatment KarTX, Karuna Therapeutics, Inc. (NASDAQ: KRTX) enjoyed a 443% gain on November 18 and a 29.2% gain on November 19 to close at $123.99. That Tuesday's close represented a 6X+ gain over the previous Frida...
Approval from the U.S. Food and Drug Administration is a big step in the life of a biotech company. It's the difference between theory and reality, between hopes and money in the bank. FDA approval not only means that a company can start selling its drugs, but also that the company might have a ...
Bear Thesis Pops Recent Stock Gains Following Positive ADCOM Results In this note, I'll focus primarily on the bear case for Amarin ( AMRN ), which has been underrepresented online, but is now in focus after Oppenheimer initiated coverage with a sell rating. This initiation is the primary ...
Amarin ( AMRN +1.3% ) is up after Aegis analyst Nathan Weinstein says the company's Vascepa is " well on the way to becoming a blockbuster drug ," which can achieve greater than $1B in annual sales and "peak sales significantly above that." More news on: Amarin Corporation plc, Healthcar...
Amarin (NASDAQ: AMRN) , a mid-cap pharma company , has long been rumored to be a buyout candidate. The core reason is that the company's prescription omega-3 treatment, Vascepa (icosapent ethyl), hit the mark in a large, placebo-controlled cardiovascular outcomes trial -- a feat no ot...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...